³X«È Åwªï±z!   ·|­ûµn¤J


 ¦^¥D­¶  ¡÷    Âå¾Ç±¡³ø  ¡÷  ¥»½g¥DÃD¡G¤T»Ä¥Ìªo¯×



 
¡i¤W¤@½g¡j[ ®ñ¦Û¥Ñ°ò¯}Ãa²Ó­M ] ¡i¤U¤@½g¡j[ »Ã¯À¯Ê¥F¯g ]

    [¤À¨É]    ¤T»Ä¥Ìªo¯×

    yoyo   µoªí©ó 2007/7/2 9:01:37



¤T»Ä¥Ìªo¯×(triglyceride)¬O¤@¥Ñ¤T­Ó¯×ªÕ»Ä¤À¤l»P¤@­Ó¥Ìªo¤À¤l୤Ʋզ¨ªº¤Æ¦Xª«¡A¥¦¬O¥ÑºÒ¤ô¤Æ¦Xª«¦X¦¨¨Ã¶J¦s©ó°Êª«¯×ªÕ²Ó­M¤ºªº ¤¤©Ê¯×ªÕ¡C ¤T»Ä¥Ìªo¯×¬O¦å²G¿é°eªº¥D­n¯×½è¡A¨C¤Ñ¬ù70¦Ü150¤½§J¶i¤J¨ÃÂ÷¶}¦å¼ß¡C¨ÅÁS²É¡]chylomicron [¤HÅ餺Åé¿n³Ì¤jªº¯×³J¥Õ]¡^±q¸z¹DÄâ±a¥~·½©Ê¤T»Ä¥Ìªo¯×¡A¸g¥Ñ¯ÝºÞ¦ÜÀR¯ß¨t²Î¡C¦b¯×ªÕ²Ó­M¤Î¦Ù¦×²Ó­Mªº·L¦åºÞ¤º¡A90%ªº¨ÅÁS²É¤¤ªº¤T»Ä¥Ìªo¯×³Q¯S©wªº¯×¸Ñ»Ã¯À²¾°£¡C¨ÅÁS²É¸g¤ô¸Ñ«á²£¥Íªº¯×ªÕ»Ä¤Î¥Ìªo¡A¶i¤J¯×ªÕ²Ó­M¤Î¦Ù¦×²Ó­M·í¦¨¯à¶q³Q§Q¥Î©Î¶J¦s¡C´Ý¾lªº¨ÅÁS²ÉÁû²É¡AÀH«á¥Ñ¨xŦ²¾°£¡C¤º·½©Ê¤T»Ä¥Ìªo¯×¡A¥D­n¬O¥Ñ¨xŦ¦X¦¨ªº·¥§C±K«×¯×³J¥Õ(VLDL: Very Low Density Lipoprotein)Äâ±a¦Ü©PÃ䪺¯×ªÕ²Ó­M¤Î¦Ù¦×²Ó­M¦P¼Ë¤]³Q·í¦¨¯à¶q³Q§Q¥Î©Î¶J¦s¡C¯×¸Ñ»Ã¯À¯à¨³³t¤À¸Ñ¤º·½©Ê¤T»Ä¥Ìªo¯×¡A¥Í¦¨¤¤¶¡±K«×¯×³J¥Õ(IDL: Intermediate Density Lipoprotein)¡C ¤j¶qÄá¨ú¥d¸ô¨½¡B¹¡©M¯×ªÕ¡BºÒ¤ô¤Æ¦Xª«¡B¤Î°sºë§¡¯à¸g¥Ñ¼W¥[·¥§C±K«×¯×³J¥Õªº§Î¦¨¦Ó¤É°ª¤T»Ä¥Ìªo¯×ªº¿@«×¡C¦Ü©ó¯Ê¥F¹B°ÊªÌ¡A«h¦]­°§C¸²µå¿}»P¯×ªÕ»Ä³Q°©Àf¦Ùªº§Q¥Î¡A¦Ó¦³¸û¦hªº¨ü½è(substrate)¨ÑÀ³¨xŦ¦X¦¨·¥§C±K«×¯×³J¥Õ¡C ­ìµo©Ê¤ÎÄòµo©Ê°ª¤T»Ä¥Ìªo¯×¦å¯g ¤É°ª¨ÅÁS²É¡B·¥§C±K«×¯×³J¥Õ¡B«e¤GªÌ¡B¤Î·¥§C±K«×¯×³J¥Õ´Ý¾lªº¿@«×·|³y¦¨¦å¼ß¤T»Ä¥Ìªo¯×¿@«×ªº¤W¤É¡C¥¿±`±¡ªp¤U¡AÀ\«á¤T»Ä¥Ìªo¯×¿@«×ªº¤É°ª¬O¥Ñ©ó¨ÅÁS²Éªº§Î¦¨¨Ã¶i¤J´`Àô¨t²Î¡C¨ÅÁS²É²M°£¥¢¯àªÌ¡A¾É­PÄY­«ªº°ª¤T»Ä¥Ìªo¯×¦å¯g(¡Ö1000 mg/dL)¡A¨Ã¸g±`§e²{Á{§É©Êªº¯ØÅ¦ª¢¡CªÅ¸¡ª¬ºAªº°ª¤T»Ä¥Ìªo¯×¦å¯g¡A¤j³¡¥÷¬O¥Ñ©ó´`Àô¨t²Î¤º·¥§C±K«×¯×³J¥Õªº¶q¤É°ª©Ò³y¦¨¡C ®a±Ú©Ê²V¦X«¬°ª¯×¦å¯g(familial combined hyperlipidemia)¬O¤@°ò¦]¥NÁ¯e¯f³y¦¨·¥§C±K«×¯×³J¥Õ¡B§C±K«×¯×³J¥Õ¡B©Î¤GªÌªº¤É°ª¡C²V¦X«¬°ª¯×¦å¯g©ó¦¨¦~«áµo¯f¡A©M°ª¯×³J¥Õ¦å¯gªº©PÃäªí²{µLÃö¡]¨Ò¦p²´Â¥¶À´³½F¡^¡A¦ýªÎ­D¤Î¿}§¿¯f·|¨Ï¤§´c¤Æ¡C¯e¯f¯S¼x¬O³J¥Õ¤¸B (apo- protein B)¥Í²£¹L¶q¡A¼W±j¨xŦ¤T»Ä¥Ìªo¯×ªº¦X¦¨¡C ¥Ñ©ó·¥§C±K«×¯×³J¥Õªº¹L¶q¥Í¦¨¡A«D¯Ø®q¯À¨Ì¿à«¬¿}§¿¯f (NIDDM¡GNon-Insulin Dependent Diabetes Mellitus or type 2)¬OÄòµo©Ê°ª¤T»Ä¥Ìªo¯×¦å¯gªº³Ì±`¨£­ì¦]¡C¯Ø®q¯À¨ã¦³¥[±j¯×³J¥Õ¯×¸Ñ»Ã¯À (lipoprotein lipase)¬¡©Êªº¥\¯à¡A¦]¦¹¯Ø®q¯À¤£¨¬ªº¿}§¿¯f±wªÌ¥Ñ©ó¯×³J¥Õ¯×¸Ñ»Ã¯À¬¡©Ê¤U­°¡A³y¦¨·¥§C±K«×¯×³J¥Õ¤À¸Ñ¥NÁÂ(catabolism) ªº¤U­°¡A¤]¥i¯à³y¦¨¤T»Ä¥Ìªo¯×¿@«×»´·Lªº¤É°ª¡F¦ý¥u­n¾A«×ªº±±¨î¦å¿}¡A¤j³¡¥÷ªº¯Ø®q¯À¨Ì¿à«¬¿}§¿¯f(IDDM¡GInsulin Dependent Diabetes Mellitus or type 1)±wªÌ¤£·|¥X²{°ª¤T»Ä¥Ìªo¯×¦å¯g¡C·¥§C±K«×¯×³J¥Õ¤À¸Ñ¥NÁ¤U­°ªº¨ä¥L­ì¦]¥]¬A¥Òª¬¸¢¾÷¯à¤£¨¬(hypothyroidism) ¡B´á¦å¯g(azotemia)¡B¤ÎµÇ©Ê¯g­Ô¸s(nephrotic syndrome)¡C ¤Þµo°ª¤T»Ä¥Ìªo¯×¦å¯gªºÃĪ«¥]¬AthiazideÃþ§Q§¿¾¯¡B¤fªAÁ×¥¥ÃÄ¡B¤Î«D¤ßŦ¿ï¾Ü©Ê¥æ·P¯«¸g¤A«¬ªýÂ_¾¯(¨Ò¦ppropranolol»Pnadolol)µ¥¡C­È±oª`·Nªº¬O¥Î©óªvÀø°ªÁx©T¾J¦å¯gªº¾ð¯×ÃþÃĪ«(¨Ò¦pcholestyramine) ¡A¦]¬°¼W¥[HMG-CoA reductase»Pphosphatidic acid phosphataseªº¬¡©Ê¥H¤Î¥[­¿¨xŦ·¥§C±K«×¯×³J¥Õ¦X¦¨»P¤Àªcªº³t²v¡A³y¦¨¦å¼ß·¥§C±K«×¯× ³J¥Õ-¤T»Ä¥Ìªo¯×¿@«×ÅãµÛªº¤É°ª¡C Ų©w¤Îµû¦ô¦¨¤H°ª¤T»Ä¥Ìªo¯×¦å¯g¤§«ü¤Þ ¦å¼ß¿@«× (mg/dL) ª¬ºA °lÂÜ«ØÄ³ §C©ó200 ¥¿±` ¨C5¦~ÂÐÀË¡C 200¦Ü400 Ãä½t°ª¦MÀI µL©ú½T«a¤ß¯f©Î2¶µ¨ä¥L«a¤ß¯f¦MÀI¦]¤l*ªÌ¡A ´£¨Ñ¶¼­¹°T®§¡AÄU»¡¹B°Ê¡A¨C¦~ÂÐÀË¡C 400¦Ü1,000 °ª¦MÀI µL©ú½T«a¤ß¯f©Î2¶µ¨ä¥L«a¤ß¯f¦MÀI¦]¤lªÌ¡A ¶}©l¶¼­¹§ïÅÜ¡AÄU»¡¹B°Ê¡A¨C¦~ÂÐÀË¡C¨ã©ú½T«a¤ß¯f©Î2¶µ¨ä¥L«a¤ß¯f¦MÀI¦]¤lªÌ¡A ¶}©l¶¼­¹»P¥Í¬¡¤è¦¡ªº§ïÅܤÎÃĪ«ªvÀø¡A­° §CªÅ¸¡¦å¼ß¤T»Ä¥Ìªo¯×¿@«×§C©ó400 mg/dL¡C ¤j©ó1,000 «D±`°ª¦MÀI ¶}©l¶¼­¹»P¥Í¬¡¤è¦¡ªº§ïÅܤÎÃĪ«ªvÀø¡A­° §CªÅ¸¡¦å¼ß¤T»Ä¥Ìªo¯×¿@«×§C©ó1,000 mg/dL¡C *«a¤ß¯f(CHD = coronary heart disease)¦MÀI¦]¤l¡G¨k©Ê¡B¿}§¿¯f¡B°ª¦åÀ£¡B§l·Ï¡B¦­µo©Ê«a¤ß¯f®a±Ú¥v¡B©ú½T¸£¦åºÞ©Î©PÃä¦åºÞ¯e¯f¡B¦å²M°ª±K«×¯×³J¥Õ-Áx©T¾J¿@«×§C©ó35 mg/dL¡BÄY­«ªÎ­D¡B¥ª¤ß«ÇªÎ¤j¡B¤ß¦åºÞ¯e¯f¤§¹B°Ê´ú¸Õ§e¶§©Ê¡B°±¸g«á¡C ¨Ì¾ÚªÅ¸¡¦å¼ß¤T»Ä¥Ìªo¯×¿@«×ªº¤ÀÃþ¤ÎªvÀø¤Wªº§PÂ_ ´ú¶q¦å¼ß¤T»Ä¥Ìªo¯×¿@«×ªº®É¾÷¡G °w¹ï¤wª¾«a°Ê¯f±wªÌ¡Aµû¦ô¯e¯fªº¶i®i¤Îªþ¥[¤ß¦åºÞ¨Öµo¯gªºµo®i¡C ¬°¤Fºë½Tµû¦ô¤U­zª¬ªpªº«a°Ê¯f¤§¦MÀI©Ê¡G·íÁ`Áx©T¾J°ª©ó²z·Q­È¡F·íÁ`Áx©T¾J©ó²z·Q­È½d³ò¡A¦ý¨ã¦³2­Ó¥H¤Wªº«a°Ê¯f¦MÀI¦]¤l¡]¨Ò¦p¡G¨k©Ê¡B°±¸g«á¤k©Ê¡B°ª¦åÀ£¡B®a±Ú¯f¥v¡B§l·Ï¤Î¿}§¿¯f¡^¡F·í¦s¦b¨ä¥L¯e¯f¡]¨Ò¦p¡G¿}§¿¯f¡B©PÃä¦åºÞ¯e¯f¡B°ª¦åÀ£¡B¤¤¤ß«¬ªÎ­D¤ÎºC©ÊµÇ¯f¡^¡C ½T©w®a±Ú©Ê°ª¯×¦å¯gªº¦s¦b¾÷²v¤Î/©Î¯ØÅ¦ª¢¦Aµoªº¥i¯à©Ê¡C °lÂÜ­°§C¦å¼ß¤T»Ä¥Ìªo¯×¿@«×ªº«DÃĪ«¤Î/©ÎÃĪ«Àøªk¡C °ª¤T»Ä¥Ìªo¯×¦å¯gªº³B¸m ³½ªoªº¸É¥R(£s-3 fatty acids)¡G£s-3 fatty acids¬O«ü±q¯×ªÕ»Äªº¥Ò°òºÝºâ°_²Ä¤T­ÓºÒ¥X²{ÂùÁä(¤£¹¡©MÁä)¡A©óÄá­¹«á6¤p®É¤º¥i¥H§¹¥þ§l¦¬¡A¨Ã´O¤J¨ÅÁS²ÉÄâ±a¦Ü¨xŦ³B¸m¡C®Ú¾Ú¼sªxªº¬y¦æ¯f¾ÇªºÃÒ¾ÚÅã¥Ü­¹¥Î³½Ãþ¡B®ü¤¤­÷¨Å°Êª«¡B©Î¨äªo¯×¡A­°§C´`Àô¨t²Î¤ºªº¯×½è¤Î¯×³J¥Õ¿@«×¡A¦P®É­°§C¤ß¦åºÞ¦º¤`²v¡C¥ÑÁ{§É¸ÕÅ窺¼Æ¾Ú«ü¥X¹¡§t£s-3 fatty acidsªº­¹ª«¡B¥H£s-3 fatty acids¨ú¥N¨ä¥Lªº­¹¥Î¯×ªÕ¡B©Î¸É¥R£s-3 fatty acids¯à°÷­°§C(±`¶W¹L50%)¨ãÄY­«°ª¤T»Ä¥Ìªo¯×¦å¯g©Î®a±Ú©Ê°ª¨ÅÁS²É¦å¯g¯f±wªºªÅ¸¡¦å¼ß¤T»Ä¥Ìªo¯×¿@«×¡CDHA (docosahexaenoic acid)¤ÎEPA (eicosapenta-enoic acid)¬O³½ªo¤¤­«­nªº£s-3 fatty acids¡C¤GªÌ¨ã¦³¬Û¦Pªº§í¨î¨xŦ¤T»Ä¥Ìªo¯×¤Î·¥§C±K«×¯×³J¥Õ¦X¦¨ªº®Ä¥Î¡F¤GªÌ¥i­°§C®a±Ú©Ê²V¦X«¬°ª¤T»Ä¥Ìªo¯×¦å¯gÀ\«á¤§·¥§C±K«×¯×³J¥Õ»P¨ÅÁS²É»W¿nªºµ{«×¤Î«ùÄò´Á¶¡¡F¤GªÌ¤]¥iÅãµÛªº­°§CIDDM¤ÎNIDDMªÅ¸¡¦å¼ß°ª¤T»Ä¥Ìªo¯×¦å¯gªºª¬ºA¡C ¹B°Ê¡GÅé¯à¬¡°Ê¸g¥Ñ¹ê¦bªº­°§C¦å¼ß¤T»Ä¥Ìªo¯×¿@«×¡B»´·Lªº¤É°ª°ª±K«×¯×³J¥Õ-Áx©T¾J¿@«×¡B¤Î´î»´Åé­«¡A¯à­°§Cµo¥Í«a¤ß¯fªº¦MÀI¨Ã´î½w²{¦³«a¤ß¯fªº¶i®i¡C ´î­«¡GªÎ­D¥Á²³¤ñ¦PÄÖ«DªÎ­DªÌ¨ã¦³¸û°ªªº¦å¼ß¤T»Ä¥Ìªo¯×»P¦å²MÁ`Áx©T¾J¿@«×¡A¥H¤Î¸û§Cªº°ª±K«×¯×³J¥Õ-Áx©T¾J¿@«×¡C¥­§¡¨C´î»´1¤½¤çÅé­«¡A¦å²MÁ`Áx©T¾J¿@«×¤U­°2-3 mg/dL¡A¦å²M§C±K«×¯×³J¥Õ -Áx©T¾J¿@«×¤ÎªÅ¸¡¦å¼ß¤T»Ä¥Ìªo¯×¿@«×¤U­°1-3 mg/dL¡C ÃĪ«¡G¥D­n¬OÅÖºû»Ä­l¥Íª«(fibric acid derivatives)¨Ò¦pbenzafibrate ¡Bfenofibrate¡B¤Îgemfibrozilµ¥©MµÒÆP»Ä(nicotinic acid) 2Ãþ¡CÃĪ«ªvÀøªºª`·N¨Æ¶µ¡G(1)À³¥J²Óµû¦ôªø´ÁªvÀø¼ç¦bªº°Æ§@¥Î¡F(2)¦]¯f±w¶¼­¹©ÎÅé­«ªº§ïÅÜ¡B¨Ö¥Î¨ä¥LÃĪ«¡Bµo¥Í¤£¨}¤ÏÀ³¡B¤Î¦~ÄÖµ¥¦]¯À»Ý­n½Õ¾ã¾¯¶q¡A¦]¦¹À³©w´ÁºÊ´úÀø®Ä¡C µ²»y ÁöµM°ª¤T»Ä¥Ìªo¯×¦å¯g»P«a¤ß¯f¨ÃµLª½±µªºÃöÁp¡A¥u¦³·í¦X¨Ö¦å²M°ª±K«×¯×³J¥ÕÁx©T¾J(HDL-C)¿@«×¤U­°®É¤~·|¤Þµo«a¤ß¯fµo¥Í²vªº¤É°ª¡F¦ý¹¡§t¤T»Ä¥Ìªo¯×ªº¯×³J¥Õ(TG-rich lipoproteins)¨ã­Pµ°½F©Ê (atherogenic) ¡A¥B¤T»Ä¥Ìªo¯×ªº¤É°ª³y¦¨¼ÆºØ¦å²G¾®¶°¦]¤lªº¼W¥[¤ÎÅÖºû³J¥Õ¤À¸Ñ¬¡©Êªº¤U­°¡A¥i¯àÀHµÛ®É¶¡«P¶iµ°½Fµw¤Æªº¯fµ{¡C·í¦å¼ß¤T»Ä¥Ìªo¯×¿@«×ÄY­«¤É°ª®É(¡Ö1000 mg/dL)¡AÁ{§É¤W¸g±`§e²{«æ©Ê¯ØÅ¦ª¢¡C¤T»Ä¥Ìªo¯×¦å¼ß¿@«×ªº´ú¶q¡AÀ³¨Ì«ØÄ³¹ê¬I¡C°ª¤T»Ä¥Ìªo¯×¦å¯gªº³B¸m¤è¦¡¤À«DÃĪ«¤ÎÃĪ«2ºØ¡A«eªÌ¥]¬A¶¼­¹¤Î¥Í¬¡«¬ºAªº½Õ¾ã¡B³½ªoªº¸É¥R(Äá¨úÄÝ©ów-3 fatty acidsªºEPA¤ÎDHA)¡B¹B°Ê¡B¤Î´î­«¡A«áªÌ«h¥]¬AÅÖºû»Ä­l¥Íª«(fibric acid derivatives)¤ÎµÒÆP»Ä(nicotinic acid) 2Ãþ¡F¦Ó¤£½×ÃĪ«¬O§_¤¶¤J¡A«DÃĪ«ªº³B¸mÀ³«ù¤§¥H«í¡C





   µoªí¥DÃD ¦^ÂÐ¥DÃD

¥Ø«e©|µL¦^ÂÐ...

¤ý®v¤÷±M·~Àð¾À¤Á¤ÕÆp¤Õ¤Þ¤Õ¤uµ{ªA°È
¥x¥_Æp¤Õ¤Á³Î ¤T­«Æp¤Õ¤Á³Î
ªO¾ôÆp¤Õ¤Á³Î ·s²øÆp¤Õ¤Á³Î
Àð¾ÀÆp¤Õ¤Á³Î,Àð­±¤Þ¤ÕÆp¤Õ,¦aªOÆp¤Õ¤Á³Î

[±ÀÂ˵û»ù¦n©±] - 4C§Ö­×³sÂêªù¥« ±M·~ºû­×¶R½æ-µ§¹q+¤â¾÷+¹q¸£+Iphone+Ipad
·s¥_¦Á¤î©± (02) 7751-9182
·s¥_¥«¦Á¤î°ÏºÖ¼w¤@¸ô86«Ñ22¸¹
·s¥_ªO¾ô©± (02) 8257-3990
·s¥_¥«ªO¾ô°Ï¥|ºû¸ô137«Ñ10¸¹
®ç¶é¤j·Ë©± (03) 387-4353
®ç¶é¥«¤j·Ë°Ï¤¤µØ¸ô210¸¹
¥x¤¤¥«°Ï©± (04) 2201-1289
¥x¤¤¥«¤¤°Ï¥x¤¤¸ô140¸¹


   ¥xÆWÂåÀø½×¾Â ¦^³»ºÝ
¦Û¾AÀ³ºô­¶½d¥»


³sµ²Àu¨}¸ê°T¤J¤fºô ¥»¯¸¤J³ò½Ã¥Í¸p95¦~«×Àu¨}°·±d¸ê°Tºô¯¸ ¥xÆWÂåÀøºô © 2006 Taiwan Inc. All Rights Reserved.

*«ØÄ³IE5.0¥H¤W¤§ÂsÄý¾¹ ¸ÑªR1024*768 ¥H¹F³Ì¨ÎÂsÄý®ÄªG* ¥þ¯¸¨Ì¤º®e¤À¯Å³W©w³B²z